Navigation Links
David Hsia, Ph.D. Joins Kinex Pharmaceuticals' Board of Directors

BUFFALO, N.Y., Sept. 15 /PRNewswire/ -- Kinex Pharmaceuticals announced that David Hsia, Ph.D. has been appointed to the Company's Board of Directors.

Dr. Hsia is a pharmaceutical veteran. He is a co-founder of Watson Pharmaceuticals, a publicly traded company listed in New York Stock Exchange (ticker: WPI). He was formerly Senior Vice President, Scientific Affairs of Watson Pharmaceuticals before his retirement. He has been involved in the development of various pharmaceutical formulations for over twenty years. Dr. Hsia received a Ph.D. in Industrial and Physical Pharmacy from Purdue University in 1975.

"Dr. Hsia is well known for his expertise in pharmaceutical development in our industry," commented Dr. Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. "As the Company moves forward, we look forward to leveraging the full breadth of David's expertise as a Board member to assist us in developing our new drug candidates," Commented Dr. Johnson Lau, Executive Chairman of the Board.

"I am delighted to have a chance to work with the team at Kinex. The company's pipeline is very strong and I am glad to have this opportunity to assist to further advance their product pipeline," commented Dr. Hsia.

About Kinex Pharmaceuticals

Kinex is a drug discovery and development company that is focused on the use of its platform technology and compound libraries to identify and develop peptide-competitive kinase inhibitors. The Company's clinical compound KX2-391 is a selective Src kinase inhibitor that is currently in Phase 1 trials for oncology. Kinex's pipeline is focused on selective inhibitors for kinase targets that are important in oncology and inflammation and immunology. The Company is located in the New York State Center of Excellence in Bioinformatics and Life Sciences, on the Buffalo Niagara Medical Campus in Buffalo, New York.

SOURCE Kinex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
2. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
3. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
4. Omeros Appoints David A. Mann to its Board of Directors
5. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
6. David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager
7. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
8. David M. Stout Joins NanoBio Corporations Board of Directors
9. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
10. Abingworth Appoints David Mayer as Partner
11. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):